BRAF and neoplasm: Exposure to the clinically used combination of the BRAF-inhibitor dabrafenib and the MEK-inhibitor trametinib (DT) leads to rapid tumor regression, followed by a drug tolerant phase, from which resistance invariably develops (Fig. 1c, d).